SEC Form 3
FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 06/16/2021 | 3. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [ VERV ] | |||||||||||||
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 404,036 | D | |
Common Stock | 80,997 | I | Kathiresan Family 2021 Irrevocable Trust |
Common Stock | 80,997 | I | Sekar Kathiresan 2021 Irrevocable Trust |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy) | (1) | 02/11/2031 | Common Stock | 431,988 | 8.24 | D | |
Stock Option (right to buy) | (2) | 09/15/2030 | Common Stock | 674,982 | 2.87 | D | |
Stock Option (right to buy) | (3) | 04/14/2029 | Common Stock | 188,995 | 1.39 | D | |
Stock Option (right to buy) | (4) | 04/14/2029 | Common Stock | 431,988 | 1.39 | D |
Explanation of Responses: |
1. The option was granted on February 12, 2021 for 431,988 shares. 25% of the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025. |
2. The option was granted on September 16, 2020 for 674,982 shares. 25% of the shares underlying the option will vest on September 16, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until September 16, 2024. |
3. The option was granted on April 15, 2019 for 188,995 shares. 25% of the shares underlying the option vested on March 25, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until March 25, 2024. |
4. The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments thereafter until July 22, 2023. |
Remarks: |
Exhibit Index: 24.1 Power of Attorney |
/s/ Andrew Ashe, Attorney-in-Fact | 06/16/2021 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |